Law Insider India

Legal News, Current Trends and Legal Insight | Supreme Court of India and High Courts

CBI Approaches Delhi HC Against Order of Lower Court in CDSCO Bribery Case

2 min read
CBI law insider

CBI law insider

Paridhi Arya

Published on June 29, 2022 at 14:42 IST

The Central Bureau of Investigation has approached to Delhi High Court against the order passed by the lower court.

The lower court had denied CBI to take the remand of the arrested officials of Central Drugs Standard Control Organisation (CDSCO) and executives of Biocon Biologics for interrogation.

The Lower Court denied the CBI twice and CBI had a fear that may the delay in interrogation will hamper the investigation and it will be difficult to catch the culprit.

The CBI then moved to Delhi High Court where parties were given notices and the matter will be heard on July 2.

The CBI had arrested Eswara Reddy, the Joint Drug Controller (JDC), while he was taking the bribe of Rs 4 lakhs from the middleman. The CBI had set the trap to arrest him in the act.

All the accused who were arrested by the CBI were sent to Tihar Jail by the Special Court for allegedly taking bribe to waive the third trial of Insuline Apart injection.

The CBI had also arrested L. Praveen Kumar who is a vice-president of Biocon Biologics in case of bribing the official.

Biocon is the parent company of Biocon Biologics, Kiran Mazumdar Shaw led the company and the allegations were denied. The public statements were released that company will cooperate with the CBI.

Guljit Sethi who looks the regulatory work of Biocon Biologics was the medium through whom the payment of 9 lakhs cleared for the bribe.

The others who are arrested by the CBI are Dinesh Dua, the director of Synergy Network India Private Limited and Animesh Kumar who is assistant drug inspector along with Guljit Sethi. All the accused were taken to Delhi.

CBI alleged that this conspiracy was made by Sethi along with Praveen Kumar who is head of National Regulatory Affairs and 9 lakhs rupees as bribe was decided to waive the third clinical trial.